Decart is launching Oasis 3, a real-time world model that generates photorealistic driving environments for autonomous ...

Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects.

Despite steady demand for obesity medications, 49% of payers who do not currently cover GLP-1s for obesity would not do so at any price, a new report from Pharmaceutical Strategies Group (PSG) found.

Neglected tropical diseases (NTDs) remain a significant global health challenge, disproportionately affecting vulnerable populations in low- and ...

The biggest names in diabetes tech gathered last weekend for the American Diabetes Association’s 86th Scientific Sessions ...